SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma

NCT03950271 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

25

Enrollment

OTHER_GOV

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine

Sponsor

Henan Cancer Hospital